New Healthcare market report from Business Monitor International: "Ghana Pharmaceuticals & Healthcare Report Q1 2013"

Boston, MA -- (SBWire) -- 03/19/2013 --BMI View: Ghana continues to outperform other markets in the region, and we predict strong growth throughout our 10 year forecast period. Ghana turns to imports for the majority of its pharmaceuticals and medical devices, but there is political drive to improve the country's domestic manufacturing capabilities. Not only would such improvements reduce the expensive import bill, but would also limit the influx of counterfeit drugs, reduce costs and pave the way for Ghana to become a regional exporter of essential drugs.

Headline Expenditure Projections:

Pharmaceuticals: GHC480mn (US$311mn) in 2011 to GHC572mn (US$319mn) in 2012; +19.1% in local currency terms and +2.6% in US dollar terms. Local currency forecast increased from Q412, due to new funding and finance agreements boosting demand.

Healthcare: GHC2.68bn (US$1.73bn) in 2011 to GHC3.14bn (US$1.75bn) in 2012; +17.4% in local currency terms and +1.1% in US dollar terms. US dollar forecast up from Q412, on account of changed foreign currency expectations.

View Full Report Details and Table of Contents

Medical devices: GHC113mn (US$73mn) in 2011 to GHC130mn (US$72mn) in 2012; +14.9% in local currency terms and -1.0% in US dollar terms. Local currency forecast increased following government investments in medical devices.

Risk/Reward Ratings: Ghana's score was stable this quarter, remaining in 18th position among the 30 key markets in the Middle East and Africa (MEA) surveyed in our Q113 pharmaceutical risk/reward ratings (RRR) matrix. Broadly speaking, Ghana is seen as having strong long-term potential for drugmakers, although low per capita spending on pharmaceuticals, coupled with widespread counterfeiting activities, will continue to moderate its RRR ranking through downward pressure on its industry rewards score.

Key Trends And Developments:

The National Health Insurance Authority announced in November 2012 that it plans to review the reimbursement price of essential drugs covered under Ghana's National Health Insurance Scheme. The NHIA is undertaking this review alongside the industry. Price increases are supposed to be implemented biannually, but it has been two years since the last rise.

Several international agencies announced funding for healthcare projects in Ghana this quarter. The EU is to offer Ghana a EUR97mn grant to fund healthcare programmes; USAID signed agreements with regional governments for a scheme to support nutritional health in women of child-bearing age and young children; and the United Nations Industrial Development Organisation will implement a EUR1mn project (funds to be split between Kenya and Ghana) to support local production of essential drugs.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Nigeria Pharmaceuticals & Healthcare Report Q1 2013
- Sweden Pharmaceuticals & Healthcare Report Q1 2013
- Bulgaria Pharmaceuticals & Healthcare Report Q1 2013
- Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2011
- Lithuania Pharmaceuticals & Healthcare Report Q1 2013
- Egypt Pharmaceuticals & Healthcare Report Q1 2013
- Slovenia Pharmaceuticals & Healthcare Report Q1 2013
- Morocco Pharmaceuticals & Healthcare Report Q1 2013
- Kuwait Pharmaceuticals & Healthcare Report Q1 2013
- Bangladesh Pharmaceuticals & Healthcare Report Q1 2013